Key Takeaways
Is Sativa or Indica Better for Anxiety?
Research has not shown that sativa or indica is better for anxiety, mainly because the labels do not reliably describe what is in the product. Researchers who analyzed 89,923 cannabis flower samples from six U.S. states concluded that the indica/hybrid/sativa system "does not reliably distinguish samples based on their chemical content"[1].
That matters for people with anxiety, because the question assumes the two categories act like different drugs. In controlled studies, the variables linked to calming or anxiety-provoking effects are the dose of THC and, in early work, terpenes such as d-limonene[3][6].
Surveys do find a consistent pattern in how users describe the labels: people more often report feeling relaxed and sleepy after indica and "paranoid/anxious" after sativa[7]. Those reports are retrospective and may partly reflect expectations the labels create.
Prevalence figures for anxiety disorders, including generalized anxiety disorder and social anxiety disorder, are on their condition pages. This article covers what the cannabis research shows.
U.S. cannabis flower samples tested to see whether indica, hybrid and sativa labels match product chemistry
Across six states, 96.5% of the samples were THC-dominant, and the three-way label did not reliably separate them by chemical content. The authors called marketing indica as sedating and sativa as energizing "specious."
"does not reliably distinguish samples based on their chemical content"
Why Indica and Sativa Labels Don't Predict Effects
In everyday use, the labels describe plant shape and expected effects, but crossbreeding has blurred them. In a 2016 interview in Cannabis and Cannabinoid Research, neurologist and psychopharmacology researcher Ethan Russo said a plant's chemistry cannot be guessed "based on its height, branching, or leaf morphology" and that only a biochemical assay shows what a plant contains[8].
"The sativa/indica distinction as commonly applied in the lay literature is total nonsense and an exercise in futility."[8]
Genetic data support that view. A 2021 study that genotyped more than 100 samples at over 100,000 genetic markers found sativa- and indica-labeled samples "genetically indistinct on a genome-wide scale"[2]. The labels tracked only a small number of terpenes whose levels are controlled by terpene synthase genes[2].
The 2022 U.S. lab analysis reached the same conclusion from chemistry[1]. Of 89,923 samples, 96.5% were THC-dominant, 1.4% were CBD-dominant and 2.2% had balanced THC and CBD[1]. The authors wrote that marketing indica-labeled products as sedating and sativa-labeled products as energizing is "specious" given the underlying chemistry[1].
One pattern did appear: a cluster of samples high in terpinolene and myrcene contained more sativa-labeled products than expected[1]. Individual strain names were a somewhat better marker of chemistry than the broad labels, though the authors described them as "far from ideal"[1].
Chemotype
A chemical phenotype of cannabis, defined by measured cannabinoid and terpene content rather than by plant shape or a marketing label. Researchers first sort products by THC-to-CBD ratio into THC-dominant, CBD-dominant and balanced chemotypes, then subdivide them by terpene profile[1].
Related Terms
Source: Smith et al., PLOS ONE, 2022
What Cannabis Users Report About Indica, Sativa and Anxiety
Belief in the labels is widespread. In a 2021 Johns Hopkins survey of 179 cannabis users, 64.2% of those who had heard of both types believed each produced unique effects[7].
Those respondents were more likely to report feeling "relaxed" and "sleepy/feel tired" after indica, and "alert," "energized" and "paranoid/anxious" after sativa[7]. The authors wrote that controlled laboratory studies are needed to confirm the differences and to clarify the role of user expectancies[7].
A two-week diary study of 101 regular users tested the labels closer to real time[9]. Most participants (78.3%) preferred one type, and cultivars classified as indica-dominant were associated with greater low-arousal effects such as feeling sluggish or slow[9].
Negative effects in that study varied with terpene content: cultivars with primary pinene were associated with fewer negative effects and those with primary caryophyllene with more[9]. Indica's calming reputation may also reflect sedation rather than lower anxiety; Russo attributed the sedation of so-called indica strains mainly to the terpene myrcene, not to CBD[8].
What Studies Found When Comparing Indica and Sativa Labels
| Study | Design | Sample | Finding on labels |
|---|---|---|---|
| Smith et al., 2022 | Lab chemistry, 6 states | 89,923 samples | Labels poorly aligned with chemistry |
| Watts et al., 2021 | Genetics and chemistry | 100+ samples | Sativa and indica genetically indistinct |
| Sholler et al., 2021 | Online survey | 179 users | More paranoia/anxiety reported after sativa |
| Okey et al., 2023 | 2-week diary study | 101 users | Indica-dominant linked to low-arousal effects |
| Stith et al., 2020 | App self-report | 2,306 sessions | Sativa linked to less overall relief; not significant by symptom |
Studies of indica and sativa labels published 2020 to 2023, none of which randomly assigned participants to indica or sativa products[1][2][7][9][4].
1Survey, diary and app studies rely on the label printed on the product and on self-rated effects.
Sources
- •Smith et al., PLOS ONE, 2022
- •Watts et al., Nature Plants, 2021
- •Sholler et al., Exp Clin Psychopharmacol, 2021
- •Okey et al., Cannabis Cannabinoid Res, 2023
- •Stith et al., J Cannabis Res, 2020
THC Dose Predicts Anxiety Effects Better Than the Label
THC has a dose-dependent relationship with anxiety. In a randomized, double-blind trial of 42 healthy adults, 7.5 mg of oral THC reduced self-reported distress after the Trier Social Stress Test compared with placebo, while 12.5 mg increased negative mood before and throughout the tasks[3].
App data point the same way. In 2,306 inhaled-flower sessions logged by 670 people, users reported lower symptom intensity in 95.51% of sessions, and anxiety ratings fell by an average maximum of 3.47 points on a 0-to-10 scale[4]. Mid and high THC levels were the main predictor of relief, while CBD levels were generally not associated with change[4].
The label added little once THC was accounted for. Flower labeled sativa was associated with less overall relief, but the difference was not statistically significant in the analyses by specific symptom[4]. Anxiety-type side effects, such as feeling anxious, paranoid or restless, appeared in fewer than 13% of sessions[4].
Potency has climbed. CDC reports that average delta-9 THC concentration in research samples almost doubled, from 9% in 2008 to 17% in 2017, and that products in online dispensaries in three states averaged 22%[11]. CDC also states that cannabis use "can cause disorientation and sometimes unpleasant thoughts or feelings of anxiety and paranoia"[12].
What Studies Show About Terpenes and CBD
Terpenes are one proposed reason that products with similar THC levels feel different, and Russo argued in 2016 that they, not the indica or sativa label, drive many observed differences[8]. Human trial data on them are sparse.
In a 2024 Johns Hopkins trial, 20 healthy adults inhaled vaporized THC with and without d-limonene, a cannabis terpene[6]. Adding 15 mg of d-limonene to 30 mg of THC significantly reduced ratings of "anxious/nervous" and "paranoid" compared with THC alone, while limonene by itself did not differ from placebo[6].
CBD has more trial data than any terpene, though the trials are small. A 2024 meta-analysis of 8 studies with 316 participants found a large pooled reduction in anxiety with CBD (Hedges' g = -0.92), with high heterogeneity between studies (I² = 83%)[13]. The authors urged caution because of the small number of trials and participants[13].
Across all cannabinoids, the evidence remains weak. A 2026 meta-analysis pooling 41 randomized trials and 4,878 participants rated the evidence that cannabinoids reduce anxiety symptoms as very low certainty (SMD -0.40)[14]. No randomized trial identified for this article compared indica-labeled with sativa-labeled products directly.
Cannabis Use, Anxiety and Dependence Risk
One randomized trial tested real-world medical cannabis access directly. Boston-area researchers assigned 186 adults seeking cannabis for pain, insomnia, or anxiety or depressive symptoms to get a medical marijuana card immediately or after 12 weeks[5].
Immediate card holders reported better sleep but no significant improvement in anxiety or depressive symptoms[5]. Cannabis use disorder developed in 17.1% of the immediate group versus 8.6% of the delayed group (adjusted odds ratio 2.88)[5]. Among participants whose main concern was anxiety or depression, the rates were 28.3% versus 10.8%[5].
CDC estimates that approximately 3 in 10 people who use cannabis have cannabis use disorder, with greater risk among people who start young and use more often[11]. CDC also lists social anxiety among conditions associated with cannabis use, an association that does not show which comes first[12].
Short-term relief and long-term change can diverge. In 5,085 app-tracked anxiety sessions, users perceived a 58% reduction in anxiety after cannabis, yet repeated use did not appear to produce longer-term reductions in anxiety, depression or stress[10]. A similar gap between reported relief and trial evidence appears in research on cannabis and ADHD.
Treatments with established trial evidence for anxiety disorders are reviewed in therapy for anxiety and anxiety medication. Data on cannabis and other substance use are on the substance use disorder page.
Frequently Asked Questions
Sources & References
- Smith CJ, Vergara D, Keegan B, Jikomes N. The phytochemical diversity of commercial Cannabis in the United States. PLOS ONE. Published 2022. Accessed October 2026. https://doi.org/10.1371/journal.pone.0267498 [Link]
- Watts S, McElroy M, Migicovsky Z, et al. Cannabis labelling is associated with genetic variation in terpene synthase genes. Nature Plants. Published 2021. Accessed October 2026. https://www.nature.com/articles/s41477-021-01003-y [Link]
- Childs E, Lutz JA, de Wit H. Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress. Drug and Alcohol Dependence. Published 2017. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC6349031/ [Link]
- Stith SS, Li X, Diviant JP, et al. The effectiveness of inhaled Cannabis flower for the treatment of agitation/irritability, anxiety, and common stress. Journal of Cannabis Research. Published 2020. Accessed October 2026. https://doi.org/10.1186/s42238-020-00051-z [Link]
- Gilman JM, Schuster RM, Potter KW, et al. Effect of medical marijuana card ownership on pain, insomnia, and affective disorder symptoms in adults: a randomized clinical trial. JAMA Network Open. Published 2022. Accessed October 2026. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790261 [Link]
- Spindle TR, Zamarripa CA, Russo E, et al. Vaporized D-limonene selectively mitigates the acute anxiogenic effects of delta-9-tetrahydrocannabinol in healthy adults who intermittently use cannabis. Drug and Alcohol Dependence. Published 2024. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC11031290/ [Link]
- Sholler DJ, Moran MB, Dolan SB, et al. Use patterns, beliefs, experiences, and behavioral economic demand of indica and sativa cannabis: a cross-sectional survey of cannabis users. Experimental and Clinical Psychopharmacology. Published 2021. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC8517044/ [Link]
- Piomelli D, Russo EB. The Cannabis sativa versus Cannabis indica debate: an interview with Ethan Russo, MD. Cannabis and Cannabinoid Research. Published 2016. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC5576603/ [Link]
- Okey SA, Waddell JT, Shah RV, et al. An ecological examination of indica versus sativa and primary terpenes on the subjective effects of smoked cannabis: a preliminary investigation. Cannabis and Cannabinoid Research. Published 2023. Accessed October 2026. https://doi.org/10.1089/can.2022.0213 [Link]
- Cuttler C, Spradlin A, McLaughlin RJ. A naturalistic examination of the perceived effects of cannabis on negative affect. Journal of Affective Disorders. Published 2018. Accessed October 2026. https://doi.org/10.1016/j.jad.2018.04.054 [Link]
- Centers for Disease Control and Prevention. Understanding your risk for cannabis use disorder. CDC. Published 2024. Accessed October 2026. https://www.cdc.gov/cannabis/health-effects/cannabis-use-disorder.html [Link]
- Centers for Disease Control and Prevention. Cannabis and mental health. CDC. Published 2024. Accessed October 2026. https://www.cdc.gov/cannabis/health-effects/mental-health.html [Link]
- Han K, Wang JY, Wang PY, Peng YCH. Therapeutic potential of cannabidiol (CBD) in anxiety disorders: a systematic review and meta-analysis. Psychiatry Research. Published 2024. Accessed October 2026. https://doi.org/10.1016/j.psychres.2024.116049 [Link]
- Bharat C, Huang X, Campbell G, et al. Cannabis and cannabinoids for the treatment of mental and substance use disorders and symptoms: a systematic review and meta-analysis of experimental and observational studies. Psychiatry Research. Published 2026. Accessed October 2026. https://doi.org/10.1016/j.psychres.2026.117380 [Link]